Possible Therapy for Platinum-Resistant Ovarian Cancer, CRLX101, Put on Fast Track by FDA
News
Cerulean Pharma announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its nanoparticle-drug conjugate (NDC) CRLX101, used in combination with paclitaxel, to treat platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer patients. ... Read more